2022
Immune checkpoint inhibitors in malignancies after liver transplantation: A systematic review and pooled analysis
Kayali S, Pasta A, Torres M, Jaffe A, Strazzabosco M, Marenco S, Giannini EG. Immune checkpoint inhibitors in malignancies after liver transplantation: A systematic review and pooled analysis. Liver International 2022, 43: 8-17. PMID: 36102312, PMCID: PMC10087158, DOI: 10.1111/liv.15419.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsLiver transplant recipientsGraft rejectionOverall survivalICI therapyCheckpoint inhibitorsICI treatmentPooled analysisSystematic reviewDe novo malignanciesAcute graft rejectionDisease control rateRecurrent hepatocellular carcinomaShorter overall survivalGraft lossNovo malignanciesLiver transplantationLT recipientsTransplant recipientsAdvanced malignanciesProspective studyControl rateCase reportHepatocellular carcinomaPatients
1997
Epstein-Barr virus-associated post-transplant lympho-proliferative disease of donor origin in liver transplant recipients
Strazzabosco M, Corneo B, Iemmolo R, Menin C, Gerunda G, Bonaldi L, Merenda R, Neri D, Poletti A, Montagna M, Del Mistro A, Faccioli A, D'Andrea E. Epstein-Barr virus-associated post-transplant lympho-proliferative disease of donor origin in liver transplant recipients. Journal Of Hepatology 1997, 26: 926-934. PMID: 9126809, DOI: 10.1016/s0168-8278(97)80262-0.Peer-Reviewed Original ResearchConceptsPost-transplant lymphoproliferative diseaseLiver transplant recipientsOrthotopic liver transplant recipientsLymphoproliferative diseaseTransplant recipientsDonor originB lymphocytesDonor B lymphocytesEBV-specific probesPost-transplant lymphomaOrthotopic liver transplantEpstein-Barr virus sequencesSolid organ transplantationPossible risk factorsLympho-proliferative diseaseNeoplastic B cellsLiver transplantEBV DNAHepatic hilumProspective studyHodgkin's lymphomaPolymerase chain reactionPotential complicationsRisk factorsReal incidence